Overview
Xanomeline-Trospium (KarXT) is an oral, investigational M1/M4-preferring muscarinic acetylcholine receptor agonist in development for the treatment of psychiatric and neurological conditions, including schizophrenia and dementia-related psychosis. KarXT preferentially stimulates muscarinic receptors in the central nervous system implicated in these conditions and has demonstrated significant benefits in reducing symptoms of psychosis in schizophrenia and Alzheimer’s disease. In 2021, Zai Lab obtained development, manufacturing and commercialization rights of KarXT in greater China from Karuna Therapeutics.
Mechanism of Action
KarXT is designed to selectively activate muscarinic acetylcholine receptors in the brain, as opposed to current antipsychotic medicines, which bind to the D2 dopamine receptor. KarXT has the potential to usher in a new class of treatment for schizophrenia and dementia-related psychosis based on its differentiated mechanism of action.